IMMUNOGLOBULIN LIGHT CHAIN (AL) AMYLOIDOSIS

Clinical trials for IMMUNOGLOBULIN LIGHT CHAIN (AL) AMYLOIDOSIS explained in plain language.

Never miss a new study

Get alerted when new IMMUNOGLOBULIN LIGHT CHAIN (AL) AMYLOIDOSIS trials appear

Sign up with your email to follow new studies for IMMUNOGLOBULIN LIGHT CHAIN (AL) AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New drug trial targets rare, debilitating protein disease

Disease control Recruiting now

This study is testing an experimental drug called etentamig (ABBV-383) for adults with AL amyloidosis, a rare disease where abnormal proteins damage organs. The trial aims to find a safe and effective dose and see if the drug can reduce disease markers in the blood and improve or…

Matched conditions: IMMUNOGLOBULIN LIGHT CHAIN (AL) AMYLOIDOSIS

Phase: PHASE1, PHASE2 • Sponsor: AbbVie • Aim: Disease control

Last updated Mar 19, 2026 14:56 UTC

IMMUNOGLOBULIN LIGHT CHAIN (AL) AMYLOIDOSIS

Get alerted when new IMMUNOGLOBULIN LIGHT CHAIN (AL) AMYLOIDOSIS trials appear

New drug trial targets rare, debilitating protein disease